Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Annals of the Rheumatic Diseases
|
April 22, 2014
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study
R A Furie, G Leon, M Thomas, et al.
The Journal of Experimental Medicine
|
October 18, 2000
Immunoglobulin heavy chain variable region gene replacement As a mechanism for receptor revision in rheumatoid arthritis synovial tissue B lymphocytes
K Itoh, E Meffre, E Albesiano, et al.
Thrombosis and Haemostasis
|
August 28, 2001
Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I
P A McNeeley, J S Dlott, R A Furie, et al.
Lupus
|
September 4, 2001
Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients
P A McNeeley, G M Iverson, R A Furie, et al.
The Journal of Rheumatology
|
November 1, 1990
L-tryptophan induced eosinophilia-myalgia syndrome
E K Chartash, W P Given, S M Vishnubhakat, et al.
Annals of the Rheumatic Diseases
|
August 22, 2015
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
J T Merrill, R F van Vollenhoven, J P Buyon, et al.
The Journal of Rheumatology
|
March 15, 2001
Treatment of systemic lupus erythematosus with LJP 394
R A Furie, J M Cash, M E Cronin, et al.
Arthritis and Rheumatism
|
August 14, 1999
A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome
N Hirose, R Williams, A R Alberts, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Annals of the Rheumatic Diseases
|
April 22, 2014
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study
R A Furie, G Leon, M Thomas, et al.
The Journal of Experimental Medicine
|
October 18, 2000
Immunoglobulin heavy chain variable region gene replacement As a mechanism for receptor revision in rheumatoid arthritis synovial tissue B lymphocytes
K Itoh, E Meffre, E Albesiano, et al.
Thrombosis and Haemostasis
|
August 28, 2001
Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I
P A McNeeley, J S Dlott, R A Furie, et al.
Lupus
|
September 4, 2001
Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients
P A McNeeley, G M Iverson, R A Furie, et al.
The Journal of Rheumatology
|
November 1, 1990
L-tryptophan induced eosinophilia-myalgia syndrome
E K Chartash, W P Given, S M Vishnubhakat, et al.
Annals of the Rheumatic Diseases
|
August 22, 2015
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
J T Merrill, R F van Vollenhoven, J P Buyon, et al.
The Journal of Rheumatology
|
March 15, 2001
Treatment of systemic lupus erythematosus with LJP 394
R A Furie, J M Cash, M E Cronin, et al.
Arthritis and Rheumatism
|
August 14, 1999
A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome
N Hirose, R Williams, A R Alberts, et al.
Page
of 2